Novartis AG
3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
Last updated:
Abstract:
The present disclosure provides a compound of Formula (I'): ##STR00001## or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R.sub.1, R.sub.2, R.sub.x, X.sub.1, n, n1, and q are as defined herein, and methods of making and using same.
Status:
Grant
Type:
Utility
Filling date:
31 Mar 2020
Issue date:
6 Jul 2021